Multiple myeloma physicians and researchers are gathering at the 17^th Congress of the European Hematology Association (EHA) to share the latest findings in the field. The meeting started today in Amsterdam and will run through Sunday, June 17.

The Myeloma Beacon will report on the most important myeloma-related findings from the meeting over the next couple of weeks.

The research presented at the meeting will cover all areas of hematology, which is the study of blood, blood-forming organs, and blood-related …

Today is the last day of this year’s American Society of Clinical Oncology (ASCO) annual meeting, which is being held in Chicago. However, the multiple myeloma-related presentations at the meeting concluded yesterday.

A poster session yesterday afternoon featured research on a wide variety of myeloma-related topics, ranging from new treatments being developed for myeloma, to currently used regimens, to second cancers, to precursor myeloma diseases, and much more.

This article summarizes research from that session related to prognostic factors, precursor myeloma …

During the upcoming annual meeting of the American Society of Clinical Oncology (ASCO), results will be presented from clin­i­cal trials involving poten­tial new drugs under devel­op­ment for the treat­ment of multiple myeloma.

In particular, results for newer, lesser known agents that are in the early stages of clin­i­cal devel­op­ment will take center stage. These agents in­clude obatoclax, siltuximab, daratumumab, and SNS01-T.

According to the recently released ASCO abstracts, the agents showed varying degrees of activity in …